Mirum Pharmaceuticals, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Mirum Pharmaceuticals, Inc. (MIRM) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $26.74 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-05
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $26.74M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $26.74M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $26.96M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $5.97M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $26.74M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $26.74M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $26.96M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.97M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $11.95M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $17.92M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $23.90M 10-K · filed 2025-02-26 |
| 2024-09-30 | $5.97M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $11.95M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $17.02M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $21.55M 10-K · filed 2024-03-15 |
| 2023-09-30 | $5.41M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $2.52M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $3.78M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $5.04M 10-K · filed 2023-03-08 |
| 2022-09-30 | $1.04M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $2.08M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $779.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.04M 10-K · filed 2022-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |